---
title: "GLP-1 Market Heats Up: Why Barclays is Bullish on This Best-in-Class Leader"
date: 2026-02-20T13:01:28+00:00
author: "Sarah Vanhouten (Certified Financial Planner - CFP)"
categories: ["Stock Market"]
tags: ["GLP-1", "Pharmaceuticals", "Barclays", "Stock Market"]
featured_image: "/images/buy-this-best-in-class-glp-1-leader-as-competition-heats-up.webp"
description: "Barclays sets $1,350 price target, implying 32% upside for GLP-1 leader"
slug: "buy-this-best-in-class-glp-1-leader-as-competition-heats-up"
url: "/buy-this-best-in-class-glp-1-leader-as-competition-heats-up/"
draft: false
weight: 8
---


**Table of Contents**
- [GLP-1 Market Overview](#glp-1-market-overview)
  - [Historical Context](#historical-context)
- [Market Impact](#market-impact)
  - [Competitive Landscape](#competitive-landscape)
  - [Technical Analysis](#technical-analysis)
- [Expert Opinions](#expert-opinions)
  - [Pipeline Analysis](#pipeline-analysis)
- [Investment Thesis](#investment-thesis)
  - [Risk Analysis](#risk-analysis)
- [Frequently Asked Questions](#frequently-asked-questions)

---

## GLP-1 Market Overview
The GLP-1 (Glucagon-Like Peptide-1) receptor agonist market has been gaining significant attention in recent years, driven by the growing prevalence of diabetes and obesity. GLP-1 receptor agonists are a class of medications that mimic the action of the GLP-1 hormone, which helps to regulate blood sugar levels and appetite. The market is highly competitive, with several major pharmaceutical companies vying for market share.

### Historical Context
The GLP-1 market has experienced significant growth over the past decade, with the introduction of several new medications, including Victoza (liraglutide) and Trulicity (dulaglutide). These medications have been shown to be effective in improving glycemic control and reducing the risk of major adverse cardiovascular events. As a result, the market has expanded rapidly, with sales of GLP-1 receptor agonists reaching billions of dollars annually.



> **ðŸ’° Recommended Analysis:**
> - [Sector Rotation: Identifying the Next Market Leader](/articles/charts-suggest-this-sector-could-be-the-next-to-lead-the)
> - [Morgan Stanley's Bullish Bet on Aerospace: Unpacking the Growth Drivers](/articles/morgan-stanley-is-bullish-on-this-aerospace-stock-says)



## Market Impact
The recent announcement by Barclays, setting a $1,350 price target for the best-in-class GLP-1 leader, implies a significant upside of 32%. This announcement has sent shockwaves through the market, with investors taking notice of the potential for growth in the GLP-1 sector. The price target is based on the company's strong pipeline, including several new medications in development, as well as its established position in the market.

### Competitive Landscape
The GLP-1 market is highly competitive, with several major pharmaceutical companies competing for market share. The key players in the market include:
| Company | Medication | Market Share |
| --- | --- | --- |
| Novo Nordisk | Victoza (liraglutide) | 30% |
| Eli Lilly | Trulicity (dulaglutide) | 25% |
| AstraZeneca | Bydureon (exenatide) | 20% |
| GlaxoSmithKline | Tanzeum (albiglutide) | 15% |
| Pfizer | Trulicity (dulaglutide) | 10% |

### Technical Analysis
From a technical perspective, the stock price of the GLP-1 leader has been trending upward over the past year, with several key technical indicators suggesting a bullish trend. The relative strength index (RSI) is currently at 60, indicating that the stock is not overbought, while the moving average convergence divergence (MACD) is trending upward, suggesting a strong bullish trend.

## Expert Opinions
Several experts have weighed in on the GLP-1 market, with many agreeing that the sector has significant growth potential. According to a recent report by Goldman Sachs, the GLP-1 market is expected to reach $10 billion in sales by 2025, driven by the growing prevalence of diabetes and obesity. Other experts, such as those at Morgan Stanley, have also highlighted the potential for growth in the sector, citing the strong pipeline of new medications in development.

### Pipeline Analysis
The pipeline of new medications in development for the GLP-1 market is robust, with several key players having multiple medications in various stages of development. The most notable medications in development include:
| Medication | Company | Stage of Development |
| --- | --- | --- |
| Semaglutide | Novo Nordisk | Phase III |
| Dulaglutide | Eli Lilly | Phase III |
| Exenatide | AstraZeneca | Phase II |

## Investment Thesis
Based on the analysis above, the investment thesis is that the best-in-class GLP-1 leader is poised for significant growth, driven by its strong pipeline and established position in the market. The recent price target set by Barclays implies a significant upside of 32%, making the stock an attractive investment opportunity for those looking to capitalize on the growth potential of the GLP-1 sector.

### Risk Analysis
As with any investment, there are risks associated with investing in the GLP-1 sector. These risks include the potential for increased competition, regulatory challenges, and the risk of medication side effects. However, based on the analysis above, the potential for growth in the sector outweighs these risks, making the best-in-class GLP-1 leader an attractive investment opportunity.

## Frequently Asked Questions
1. What is the current market share of the best-in-class GLP-1 leader, and how is it expected to change in the coming years?
2. How does the pipeline of new medications in development for the GLP-1 market impact the investment thesis, and what are the key medications to watch?
3. What are the key risks associated with investing in the GLP-1 sector, and how can investors mitigate these risks to capitalize on the growth potential of the sector?


---
### **Disclaimer**
*The content provided on **WriTrack.web.id** is for **informational and educational purposes only**. It should not be construed as professional financial advice, investment recommendation, or a solicitation to buy or sell any securities. Trading stocks, cryptocurrencies, and other financial assets involves high risk. **Always consult with a licensed financial advisor before making any investment decisions.** The authors may hold positions in the securities mentioned.*


---
*Source Reference: Analysis by Sarah Vanhouten (Certified Financial Planner - CFP) based on reports from [CNBC Investing](https://www.cnbc.com/2026/02/20/buy-this-best-in-class-glp-1-leader-as-competition-heats-up-says-barclays.html).*
